Cookson Peirce & Co. Inc. Has $23.63 Million Holdings in Eli Lilly and Company $LLY

Cookson Peirce & Co. Inc. boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 46.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,988 shares of the company’s stock after purchasing an additional 7,011 shares during the quarter. Cookson Peirce & Co. Inc.’s holdings in Eli Lilly and Company were worth $23,630,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. XML Financial LLC raised its stake in Eli Lilly and Company by 21.0% during the 4th quarter. XML Financial LLC now owns 1,664 shares of the company’s stock valued at $1,788,000 after purchasing an additional 289 shares during the last quarter. Nemes Rush Group LLC raised its stake in Eli Lilly and Company by 0.6% during the 4th quarter. Nemes Rush Group LLC now owns 15,361 shares of the company’s stock valued at $16,508,000 after purchasing an additional 94 shares during the last quarter. Havemeyer Place LP acquired a new position in Eli Lilly and Company during the 4th quarter valued at $1,299,000. 111 Capital raised its stake in Eli Lilly and Company by 210.4% during the 4th quarter. 111 Capital now owns 2,030 shares of the company’s stock valued at $2,182,000 after purchasing an additional 1,376 shares during the last quarter. Finally, Lowe Brockenbrough & Co. Inc. raised its stake in shares of Eli Lilly and Company by 26.0% in the 4th quarter. Lowe Brockenbrough & Co. Inc. now owns 8,469 shares of the company’s stock valued at $9,101,000 after buying an additional 1,749 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark reversed its earlier exclusion and will now cover Eli Lilly’s Zepbound, a meaningful reimbursement win that could expand patient access and bolster obesity-drug sales. Article Title
• Positive Sentiment: WeightWatchers Med+ is now available through LillyDirect, reinforcing Lilly’s distribution ecosystem and strengthening its leadership in chronic weight management. Article Title
• Positive Sentiment: Lilly announced a new Phase 2b obesity trial for macupatide–eloralintide, adding another potential growth driver to its weight-loss pipeline beyond current GLP-1 products. Article Title
• Positive Sentiment: Jim Cramer highlighted Lilly as a potential winner against competitors, with attention on its new pill version of its weight-loss drug and broader competitive advantages. Article Title
• Positive Sentiment: Analysts and market commentary continue to frame LLY as a long-term winner, citing strong execution, deal-making, and diversification efforts beyond obesity drugs. Article Title
• Neutral Sentiment: Lilly also received coverage around its Phase 3 Libretto-432 cancer study and a $1.9 billion Ascidian partnership, both of which support the pipeline but are longer-term in nature. Article Title
• Neutral Sentiment: Broader health-care sector commentary and stock-screen articles were generally supportive, but they are less likely to be a direct driver of LLY’s move than the CVS and pipeline news. Article Title

Eli Lilly and Company Stock Up 0.7%

LLY opened at $1,133.15 on Friday. The firm’s 50-day simple moving average is $974.59 and its 200-day simple moving average is $1,013.04. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,166.29. The firm has a market cap of $1.07 trillion, a price-to-earnings ratio of 40.25, a PEG ratio of 1.24 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same quarter in the prior year, the firm earned $3.34 EPS. The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on LLY shares. CICC Research increased their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research note on Wednesday, February 11th. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 2nd. Guggenheim restated a “buy” rating and issued a $1,183.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, May 5th. Cantor Fitzgerald increased their price objective on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the company an “overweight” rating in a research note on Friday, May 1st. Finally, Weiss Ratings cut shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, May 19th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $1,227.00.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.